Health and Fitness Health and Fitness
Thu, May 10, 2012
Wed, May 9, 2012
Tue, May 8, 2012
Mon, May 7, 2012
Sat, May 5, 2012
Fri, May 4, 2012
Thu, May 3, 2012
[ Thu, May 03rd 2012 ] - Market Wire
00 p.m. EDT
Wed, May 2, 2012
Tue, May 1, 2012
Mon, April 30, 2012
[ Mon, Apr 30th 2012 ] - Market Wire
Hologic to Acquire Gen-Probe
Sun, April 29, 2012
Sat, April 28, 2012
Fri, April 27, 2012
Thu, April 26, 2012
Wed, April 25, 2012

Omeros to Present at Deutsche Bank Securities Health Care Conference


Published on 2012-05-02 04:06:58 - Market Wire
  Print publication without navigation


Omeros to Present at Deutsche Bank Securities Health Care Conference -- SEATTLE, May 2, 2012 /PRNewswire/ --

Omeros to Present at Deutsche Bank Securities Health Care Conference

[ ]

SEATTLE, May 2, 2012 /PRNewswire/ -- Omeros Corporation (NASDAQ: [ OMER ]), a biopharmaceutical company committed to discovering, developing and commercializing products focused on inflammation, bleeding and disorders of the central nervous system, today announced that Gregory A. Demopulos, M.D., chairman and chief executive officer, is scheduled to present at the Deutsche Bank Securities 37th Annual Health Care Conference next week. The presentation is scheduled for 10:00 a.m. Eastern Time on Wednesday, May 9, 2012.

The presentation will be webcast. The live and archived webcasts can be accessed on the "Events" page of the Company's website at [ www.omeros.com ].  

About Omeros Corporation
Omeros is a clinical-stage biopharmaceutical company committed to discovering, developing and commercializing products targeting inflammation, coagulopathies and disorders of the central nervous system. The Company's most clinically advanced product candidates are derived from its proprietary PharmacoSurgery™ platform designed to improve clinical outcomes of patients undergoing a wide range of surgical and medical procedures. Omeros has four ongoing clinical development programs. Omeros may also have the near-term capability, through its GPCR program, to add a large number of new drug targets and their corresponding compounds to the market. Behind its clinical candidates and GPCR platform, Omeros is building a diverse pipeline of protein and small-molecule preclinical programs targeting inflammation, coagulopathies and central nervous system disorders.

SOURCE Omeros Corporation

[ Back to top ]

RELATED LINKS
[ http://www.omeros.com ]


Publication Contributing Sources